Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 3/20 | 0.61 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | ALB | P02768 | 1/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.61 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.61 |
| ▸ | HPGD | P15428 | 1/20 | 0.61 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.61 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.61 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.61 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.61 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.61 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.61 |
| ▸ | HTR2B | P41595 | 1/20 | 0.61 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.61 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.61 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22426175 | 0.86 | GABRA1 (0.57) | GABRA1GABRB2KDM4ELMNAALB | |
| SCHEMBL1432756 | 0.84 | GABRA1 (0.65) | GABRA1GABRB2KDM4ELMNAALB | |
| SCHEMBL5566700 | 0.83 | ALDH1A1 (0.65) | GABRA1GABRB2KDM4ESMN1; SMN2NPC1 | |
| SCHEMBL1430476 | 0.81 | GABRA1 (0.61) | GABRA1GABRB2KDM4ELMNAALB | |
| SCHEMBL29621620 | 0.81 | GABRA1 (0.61) | GABRA1GABRB2KDM4ELMNAALB | |
| SCHEMBL4253068 | 0.81 | GABRA1 (0.61) | GABRA1GABRB2KDM4ELMNAALB | |
| SCHEMBL1691670 | 0.81 | GABRA1 (0.65) | GABRA1GABRB2KDM4ELMNAALB | |
| SCHEMBL12500189 | 0.81 | GABRA1 (0.61) | GABRA1GABRB2KDM4ELMNAALB | |
| SCHEMBL13368336 | 0.80 | ALDH1A1 (0.63) | GABRB2KDM4EALBOPRK1GABRA2 | |
| SCHEMBL7903910 | 0.80 | GABRA1 (0.61) | GABRA1GABRB2KDM4ELMNAALB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114591320-B | Preparation method of zolpidem | 鲁南制药集团股份有限公司 | 2026-02-06 | — | — | CN | disclosed |
| CN-114591320-A | Preparation method of zolpidem | 鲁南制药集团股份有限公司 | 2022-06-07 | — | — | CN | disclosed |
| CN-114591320-A | Preparation method of zolpidem | 鲁南制药集团股份有限公司 | 2022-06-07 | — | — | CN | disclosed |
| US-7943611-B2 | Imidazo[1,2-A]pyridin-3-yl-acetic acid hydrazides, processes, for their preparation and pharmaceutical uses thereof | FERRER INTERNATIONAL, S.A. (ES) | 2011-05-17 | — | — | US | disclosed |
| EP-1682549-B1 | IMIDAZO[1,2-A]PYRIDINE ANXIOLYTICS | SEPRACOR INC (US) | 2010-09-22 | — | — | EP | disclosed |
| EP-1682549-B1 | IMIDAZO[1,2-A]PYRIDINE ANXIOLYTICS | SEPRACOR INC (US) | 2010-09-22 | — | — | EP | disclosed |
| US-7723324-B2 | Imidazo[1,2-A]pyridine anxiolytics | SEPRACOR, INC. (US) | 2010-05-25 | — | — | US | disclosed |
| US-7723324-B2 | Imidazo[1,2-A]pyridine anxiolytics | SEPRACOR, INC. (US) | 2010-05-25 | — | — | US | disclosed |
| US-7566725-B2 | Imidazo[1,2-A] pyridine anxiolytics | SEPRACOR INC. (US) | 2009-07-28 | — | — | US | disclosed |
| US-7566725-B2 | Imidazo[1,2-A] pyridine anxiolytics | SEPRACOR INC. (US) | 2009-07-28 | — | — | US | disclosed |
| US-20080096867-A1 | Imidazo[1,2-A] Pyridine Anxiolytics | SEPRACOR INC. (US) | 2008-04-24 | — | — | US | disclosed |
| US-20070043074-A1 | IMIDAZO[1,2-A] PYRIDINE ANXIOLYTICS | SEPRACOR INC. (US) | 2007-02-22 | — | — | US | disclosed |
| US-20070043074-A1 | IMIDAZO[1,2-A] PYRIDINE ANXIOLYTICS | SEPRACOR INC. (US) | 2007-02-22 | — | — | US | disclosed |
| US-7148353-B2 | Imidazo[1,2-a] pyridine anxiolytics | SEPRACOR INC. (US) | 2006-12-12 | — | — | US | disclosed |
| EP-1682549-A2 | IMIDAZO[1,2-A]PYRIDINE ANXIOLYTICS | Sepracor Inc. (US) | 2006-07-26 | — | — | EP | disclosed |
| US-20050171144-A1 | Imidazo[1,2-a] pyridine anxiolytics | SEPRACOR INC. (US) | 2005-08-04 | — | — | US | disclosed |
| WO-2005063297-A2 | MELATONIN COMBINATION THERAPY FOR IMPROVING SLEEP QUALITY | SEPRACOR INC. (US) | 2005-07-14 | — | — | WO | disclosed |
| WO-2005060968-A1 | COMBINATION OF A SEDATIVE AND A NEUROTRANSMITTER MODULATOR, AND METHODS FOR IMPROVING SLEEP QUALITY AND TREATING DEPRESSION | SEPRACOR INC. (US) | 2005-07-07 | — | — | WO | disclosed |
| WO-2005044818-A2 | IMIDAZO[1,2-A]PYRIDINE ANXIOLYTICS | SEPRACOR, INC. (US) | 2005-05-19 | — | — | WO | disclosed |
| WO-2005044818-A2 | IMIDAZO[1,2-A]PYRIDINE ANXIOLYTICS | SEPRACOR, INC. (US) | 2005-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043074-A1 | IMIDAZO[1,2-A] PYRIDINE ANXIOLYTICS | CNR1, CNR2, GABRA5 | GABRA1 4/4885GABRB2 25/4885KDM4E 995/4885 |
| US-20050171144-A1 | Imidazo[1,2-a] pyridine anxiolytics | CNR1, CNR2, GABRA5 | GABRA1 4/4885GABRB2 25/4885KDM4E 995/4885 |
| US-20080096867-A1 | Imidazo[1,2-A] Pyridine Anxiolytics | MTNR1B, ADORA2B, ADRA2B | GABRA1 37/4885GABRB2 13/4885KDM4E 796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.